IASO Bio reports 90 percent response rate for CAR-T therapy
September 28, 2026 | 11:41
Biotechnology developer IASO Bio announced a 90 percent objective response rate from first-in-human clinical trials evaluating its IASO206 in vivo CAR-T candidate for multiple myeloma.
Mobile Version